Wakamoto Pharmaceutical Co.,Ltd.
Notice Regarding Change of Major Shareholder, the Principal Shareholder
Notification of change in major shareholder. New principal shareholder is Asset Value Investors Limited (UK), with voting rights increased to 11.70%. Lohaco? Wait: note: original says ロート製薬; translated as Rohto Pharmaceutical Co., Ltd. remains as second place. No further outlook described.
Key Figures
- Voting rights of the new principal shareholder: 40,560 shares
- Number of shares owned by the new principal shareholder: 4,056,000 shares
- Voting rights of Rohto Pharmaceutical: 39,719 shares
AI要約
Overview of the Change
This press release, based on the submission of the Large-Scale Shareholding Report dated August 27, 2026, confirms a change in our major shareholder, the principal shareholder. The new principal shareholder is Asset Value Investors Limited (London, UK), whose voting rights were 40,560 as of August 20, 2026, representing 11.70% of total voting rights, ranking it first.
Outlook and Impact
This matter is based on the submission of the Large-Scale Shareholding Report, and no specific outlook is stated. With Rohto Pharmaceutical Co., Ltd. no longer a major shareholder, the shareholder ranking shifted to 2nd place, but the specific impact on business strategy or capital policy remains unknown at this time.
Wakamoto Pharmaceutical Co.,Ltd.
Company overview · Stock price · Financial data · All IR
